Syncona receives a boost from 20% increase in value of Freeline
Investor and founder in life science companies Syncona (SYNC) said on Tuesday it had raised an additional funding for gene therapy specialist Freeline at a higher valuation giving Syncona shares a 3.5% boost to 248p.The fund raise...
30 June 2020